Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2a/2b multicenter study of AG-946 in patients with anemia due to lower-risk myelodysplastic syndromes
    Meeting Abstract

    Al-Samkari, H.; Fenaux, P.; Sekeres, M. A.; Stein, E.; Sallman, D. A.; Brunner, A. M.; Gurov, X. D.; Yin, O.; Frisbie, M.; Xiao, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Safety and tolerability of pirtobrutinib monotherapy in patients with B-cell malignancies who were previously intolerant to a covalent BTK inhibitor: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Shah, N. N.; Wang, M. L.; Brown, J. R.; Patel, K.; Woyach, J. A.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; Alencar, A. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • MYLOX-1: An open-label, phase IIa study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral LOXL2 inhibitor, GB2064, in myelofibrosis
    Meeting Abstract

    Verstovsek, S.; Mascarenhas, J.; Rampal, R. K.; Cilloni, D.; Harrison, C.; Jacoby, B.; Slack, R. J.; Aslanis, V.; Singh, B.; Lindmark, B.
    Blood (2022)

    Fulltext@MSK | Save
  • Asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase (CML-CP)-H. Jean Khoury Cure CML Consortium study
    Meeting Abstract

    Atallah, E. L.; Visotcky, A.; Flynn, K. E.; Zhang, M. J.; Radich, J. P.; Yang, J.; Oehler, V. G.; Tantravahi, S. K.; Smith, B. D. D.; Ibarz, J. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Long-term molecular testing and clinical response of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: 5-year follow-up from SIMPLICITY, a prospective, observational study
    Meeting Abstract

    Cortes, J. E.; Goldberg, S. L.; Paquette, R.; Williams, L. A.; Hehlmann, R.; Michallet, M.; Gambacorti-Passerini, C.; Tang, D. R.; DeGutis, I. S.; McBride, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119
    Meeting Abstract

    Bar-Natan, M.; Mascarenhas, J.; Gerds, A. T.; Mesa, R.; Gupta, V.; Kremyanskaya, M.; Dougherty, M.; Fabris, F.; Johnson, K.; Yu, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Escape from type II JAK2 inhibition in MPN depends on AXL/MAPK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J.; Ghosh, N.; Buczak, K.; Passweg, J.; Angelillo-Scherrer, A.; Dirnhofer, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Updated outcomes from the historical control study SCHOLAR-3 contextualizing ZUMA-3 results of brexucabtagene autoleucel (KTE-X19) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
    Meeting Abstract

    Shah, B. D.; Ghobadi, A.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Cassaday, R. D.; Leguay, T.; Bishop, M. R.; Topp, M. S.; Tzachanis, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial results from SELECT-AML-1, a Phase 2 Study of tamibarotene in combination with venetoclax and azacitidine in RARA-positive newly diagnosed AML patients ineligible for standard induction chemotherapy
    Meeting Abstract

    Kambhampati, S.; McMahon, C. M.; Eghtedar, A.; Pollyea, D. A.; de Botton, S.; Pigneux, A.; Cherry, M.; Ball, B. J.; Borthakur, G.; Cluzeau, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage
    Meeting Abstract

    Vekariya, U. M.; Sullivan-Reed, K.; Toma, M.; Nieborowska-Skorska, M.; Le, B. V.; Caron, M. C.; Kukuyan, A. M.; Podszywalow-Bartnicka, P.; Chitrala, K.; Atkins, J.; more...
    Blood (2022)

    Fulltext@MSK | Save